Health Canada has approved a new antibody drug to help protect babies from serious illness caused by respiratory syncytial virus, or RSV. Nirsevimab, also known by its brand name Beyfortus, was authorized on April 19. It was developed by AstraZeneca and Sanofi…
Read More
About The Author
